Representing CMK Select at Regeneron as a Project Manager for the US Market Access Strategy – Oncology Team, this role will support market access commercialization engagements and activities for one of Regeneron’s products in multiple indications.

Working on LAGEVRIO Global Market Access and Global Oncology (HCP) projects.

Oncology Lead/Program Manager, Oncology Global Market Access Team February 2021 to May 1, 2022• Led the development of 24 Payer Value Tools across franchise of indications for KEYTRUDA.• Work collaboratively with nine oGMAx stakeholders, and 17 teams involving Global Marketing, CORE, Merck Research Labs, and Medical Affairs.o Led meetings with internal teams and advertising agencies to identify and develop resources needed to support a specific customer behavior and/or business objective.o Assisted with AOR selections, price negotiations, and SOW creations.o Acted as liaison between agencies and internal Merck departments.o Initiated and managed content development process for materials with external agencies and managed project timelines.o Provided guidance to agencies to develop and refine Payer Value Tools.o Gained CORE, Medical Affairs and Global Marketing approval of Payer Value Tools.o Obtained final oGMAx Leadership approval of Payer Value Tools.• Mentored oGMAx Program Manager: Trained and mentored a colleague to develop project management, stakeholder management, agency management and budget management skills. • Leading the development of the Payer Value Deck Update for LAGEVRIO.

Program Manager, Acute Care Hospital Franchise December 2016 to February, 2021• Led the development of 30 Payer Resources for Acute Care Hospital, Infectious Disease, Respiratory and Rheumatology Franchise involving: BRIDION, ZERBAXA, RECARBRIO, PREVYMIS, PIFELTRO/DELSTRIGO, Islatravir, ZEPATIER, LYFNUA and SIMPONI.

• Initiated pilot of Aquent “C-Level” projects for JANUVIA/JANUMET.• Managed the development of 95 Health Care Professional Resources including a 90 second Today I video.

O'Laughlin & Associates is a health care management consulting firm based in Wilmington, Delaware. Recent assignments:♦ On assignment at LifeScan, a Johnson & Johnson diabetes company, I led multiple cross-functional project teams as global commercial lead, and created, maintained and presented global brand, product and commercial plans to global commercial team, R&D partners and board-level forums. I liaised with key commercial regions and supported downstream marketing with product launches beyond lead or initial region introductions. Other assignments:♦ Led dialog with ArchCare, Diocese of New York to explore a PACE-based health care solution for the friar and Dutchess County communities located near the St. Lawrence Friary in Beacon, NY. ♦ Provided strategic marketing consulting to an award-winning Maryland advertising agency, resulting in three new projects for agency.♦ Revised marketing plan for leading international medical device firm; provided strategic insights, and identified additional opportunities for development.♦ Identified strategic needs for process improvement, staff development and client services for an international medical publishing company; supervised team of two medical directors, six medical writers, and two program managers.

I provided pro bono involvement with the staff and students at the Jefferson School of Population Health.

Developed health-care professional, consumer marketing strategies and tactical programs for the treatment of Alzheimer’s disease with RAZADYNE®ER, a Johnson & Johnson brand. • Developed brand positioning, segmentation strategy and messaging.• Directed health care professional and consumer web site development.• Managed $3 million budget.

Led the tactical execution for the launch of SEROQUEL into the primary care new market, including execution of a market segmentation strategy for primary care physicians.• Developed and managed 1,300 peer-to-peer programs involving 35,500 primary care physicians. • Coordinated convention strategy; organized activities at nine conventions with budgets totaling over $800,000.• Managed $11 million budget.

• Led integreation of Global and U.S. strategy development for nine compounds in early development, ranging from preclinical/clinical development to market research and commercialization.• Led non-small cell lung cancer education and commercial strategy.• Performed early biomarker assessment market research for Iressa therapy. • Performed commercial opportunity analysis for two in-licensing opportunities.• Leading pricing and reimbursement strategy development.

Led heart failure launch strategy and life cycle management including tactical plan execution for customer marketing, medical education, e-promotion, and public relations for physicians, hospitals and managed care organizations:• Initiated a comprehensive launch plan. • Developed communication strategy for cardiology and primary care physician audiences to disseminate results from MERIT-HF Study. • Partnered with Heart Failure Society of America, American College of Cardiology and American Heart Association to review and revise treatment guidelines for heart failure. • Created multi-lingual and low literacy patient education programs (heart failure starter kits, award winning video programs).• Partnered with Jefferson Medical College of Thomas Jefferson University in Philadelphia and University of Pittsburgh Medical Center (UPMC) to survey physicians about the use of beta-blockers in the treatment of heart failure. The survey was published and publicized as Heart Failure Report Card and later presented on-line at www.heartfailurereportcard.org.• Managed annual budgets ranging from $11 million to $35 million.• Supervised four managers.• Results: achieved 35% growth year over year and recorded $1 billion in annual sales in 2003

Developed positioning and creative blueprint for bucindilol, a new beta-blocker for the treatment of heart failure• Launched a new advertorial campaign to set stage for product introduction.• Planned and supervised nine symposia publications.• Initiated and managed 20 promotional programs.

Initiated the development of 22 managed market programs in support of PRILOSEC; at that time, the world’s largest pharmaceutical brand.

Account Manager Developed three managed care programs for ZESTRIL® that resulted in 14% growth in new prescriptions, and market leadership.